Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. (Q40026048)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 January 2008

Language	Label	Description	Also known as
English	Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.	scientific article published on 10 January 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

author name string

Robert A Ogert

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Lisa Wojcik

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Catherine Buontempo

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Lei Ba

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Peter Buontempo

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Robert Ralston

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Julie Strizki

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

John A Howe

8

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

language of work or name

0 references

publication date

10 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

373

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

387-399

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Assessing chemokine co-receptor usage in HIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 integrase inhibitors: an emerging clinical reality

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

V3: HIV's switch-hitter

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Structure of a V3-containing HIV-1 gp120 core

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

CCR5 interactions with the variable 3 loop of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 coreceptor usage, transmission, and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Chemokine antagonists as therapeutics: focus on HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2007.12.009

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40026048&oldid=1771975772"